Skin bacterial richness and diversity in intensive care unit patients with severe pneumonia

Sifen Lu1, Wengeng Zhang1, Xiaojin Li2

  • 1Precision Medicine Key Laboratory of Sichuan Province and Precision Medicine Center, West China Hospital, Sichuan University, Chengdu, China.

Abstract

Insights

Severe pneumonia patients in the intensive care unit (ICU) show reduced skin bacterial diversity. This skin microbiota alteration is linked to healthcare-associated infections, highlighting the need for pathogen control.

Area of Science:

  • Microbiology
  • Intensive Care Medicine
  • Infectious Diseases

Background:

  • Patients with severe pneumonia in intensive care units (ICUs) face high mortality risks.
  • The role of the skin microbiome in ICU patient outcomes, particularly those with severe pneumonia, is not well understood.
  • Understanding skin bacterial composition is crucial for managing severe pneumonia in ICUs.

Purpose of the Study:

  • To investigate differences in skin bacterial richness and diversity between severe pneumonia patients in the ICU and healthy controls.
  • To identify specific bacterial taxa that are differentially abundant on the skin of ICU patients with severe pneumonia.

Main Methods:

  • 16S ribosomal RNA sequencing was used to analyze skin bacterial communities.
  • The Quantitative Insights Into Microbial Ecology (QIIME) pipeline was employed for data analysis.
  • Skin bacterial diversity and taxonomic distribution were compared between the patient group (PG) and control group (CG).

Main Results:

  • Skin bacterial diversity was significantly lower in the ICU patient group compared to the healthy control group.
  • Specific bacteria, including Staphylococcus, Acinetobacter, Stenotrophomonas, Enterococcus, Halomonas, and Brevibacillus, were found in different abundances in the patient group.
  • Many of these differentially abundant bacteria were also detected in respiratory tract samples from the same patients.

Conclusions:

  • Healthcare-associated infections in ICU patients with severe pneumonia are strongly associated with alterations in the skin microbiota.
  • Preventing and controlling skin bacterial pathogens is essential for improving outcomes in these vulnerable patients.

Related Concept Videos

Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
467
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
355
Sputum Studies II: Culture and Sensitivity01:20

Sputum Studies II: Culture and Sensitivity

Description
Sputum culture and sensitivity is a medical procedure used to diagnose bacterial infections in the respiratory tract and select the most appropriate antibiotics for treatment. This process involves analyzing sputum samples of thick and opaque secretions produced in the lungs and airways. These samples are collected from patients and then sent to the laboratory for analysis.
The test can identify various pathogens responsible for respiratory infections, including Streptococcus,...
648
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
464
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:
703